LONA - LeonaBio, Inc. News

LeonaBio Enrolls 500th Subject In Phase 3 ELAINE-3 Trial For Lasofoxifene With Abemaciclib

On August 26, 2026, LeonaBio, Inc. (the "Company") announced that it had enrolled the 500th

Mizuho Maintains Outperform on LeonaBio, Lowers Price Target to $15

Mizuho analyst Graig Suvannavejh maintains LeonaBio (NASDAQ:LONA) with a Outperform and lowers th

Citizens Maintains Market Outperform on LeonaBio, Lowers Price Target to $17

Citizens analyst Jason N. Butler maintains LeonaBio (NASDAQ:LONA) with a Market Outperform and lo

LeonaBio Q2 EPS $(0.80) Beats $(1.36) Estimate

LeonaBio (NASDAQ:LONA) reported quarterly losses of $(0.80) per share which beat the analyst consens

LeonaBio Reports Second Quarter 2026 Financial Results and Provides Business Update

On Track to Complete Enrollment of Phase 3 ELAINE-3 Clinical Trial of Lasofoxifene in ER-positive (E

LeonaBio’s Lead Product Candidate, Lasofoxifene, To Be Featured In Multiple Presentations At Dava On

LeonaBio, Inc. (NASDAQ:LONA), a clinical-stage biopharmaceutical company dedicated to the developmen

LeonaBio to Highlight Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastatic Brea

BOTHELL, Wash., Aug. 12, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ: LONA), a clinical-stage bi

Citizens Upgrades LeonaBio to Market Outperform, Announces $18 Price Target

Citizens analyst Jason N. Butler upgrades LeonaBio (NASDAQ:LONA) from Market Perform to Market Ou

12 Health Care Stocks Moving In Monday's Pre-Market Session

Gainers Tenon Medical (NASDAQ:TNON) shares increased by 115.8% to $0.76 during Monday's pre-mar

12 Health Care Stocks Moving In Wednesday's After-Market Session

LeonaBio Presents on ATH-1105 at 5th Annual ALS Drug Development Summit

BOTHELL, Wash., June 04, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ: LONA), a clinical-stage bi

LeonaBio to Participate in Upcoming Medical and Industry Meetings in June

BOTHELL, Wash., May 27, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ: LONA), a clinical-stage bio

Piper Sandler Initiates Coverage On LeonaBio with Overweight Rating, Announces Price Target of $20

Piper Sandler analyst Kelsey Goodwin initiates coverage on LeonaBio (NASDAQ:LONA) with a Overweig

LeonaBio Q1 EPS $(1.73) Beats $(2.50) Estimate

LeonaBio (NASDAQ:LONA) reported quarterly losses of $(1.73) per share which beat the analyst consens

LeonaBio Reports First Quarter 2026 Financial Results and Provides Business Update

Advancing Phase 3 Lasofoxifene Development Program of Novel Selective Estrogen Receptor Modulator, a

LeonaBio Enhances Board of Directors with Appointments of Fred Callori, J.D., Natalie Holles and Pet

BOTHELL, Wash., May 07, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ: LONA), a clinical-stage bio

seekingalpha.com

LeonaBio, Inc. (LONA) Discusses Modulation and Combination Strategies in ER-Positive Metastatic Brea

LeonaBio to Host Virtual Key Opinion Leader Event Highlighting Potential of Lasofoxifene in Treatmen

Management to be Joined by Two Clinical Leaders in the Breast Cancer Field Expected to Complete Enr

12 Health Care Stocks Moving In Wednesday's Intraday Session

LeonaBio Q4 EPS $(2.77) Misses $(0.84) Estimate

LeonaBio (NASDAQ:LONA) reported quarterly losses of $(2.77) per share which missed the analyst conse

LeonaBio Reports Full Year 2025 Financial Results and Provides Business Update

Acquired License to Phase 3 Lasofoxifene Development Program of Novel Selective Estrogen Receptor Mo

Contrasting Athira Pharma (NASDAQ:LONA) & Prime Medicine (NASDAQ:PRME)

Prime Medicine (NASDAQ: PRME - Get Free Report) and Athira Pharma (NASDAQ: LONA - Get Free Report) a

Financial Analysis: Prime Medicine (NASDAQ:PRME) & Athira Pharma (NASDAQ:LONA)

Athira Pharma (NASDAQ: LONA - Get Free Report) and Prime Medicine (NASDAQ: PRME - Get Free Report) a

Athira Pharma (NASDAQ:LONA) and Liminatus Pharma (NASDAQ:LIMN) Head to Head Analysis

Athira Pharma (NASDAQ: LONA - Get Free Report) and Liminatus Pharma (NASDAQ: LIMN - Get Free Report)

Reviewing Athira Pharma (NASDAQ:LONA) & Liminatus Pharma (NASDAQ:LIMN)

Liminatus Pharma (NASDAQ: LIMN - Get Free Report) and Athira Pharma (NASDAQ: LONA - Get Free Report)

Prime Medicine (NASDAQ:PRME) and Athira Pharma (NASDAQ:LONA) Head to Head Review

Athira Pharma (NASDAQ: LONA - Get Free Report) and Prime Medicine (NASDAQ: PRME - Get Free Report) a

Financial Contrast: Athira Pharma (NASDAQ:LONA) and Liminatus Pharma (NASDAQ:LIMN)

Liminatus Pharma (NASDAQ: LIMN - Get Free Report) and Athira Pharma (NASDAQ: LONA - Get Free Report)

Athira Pharma (NASDAQ:LONA) vs. Prime Medicine (NASDAQ:PRME) Financial Analysis

Athira Pharma (NASDAQ: LONA - Get Free Report) and Prime Medicine (NASDAQ: PRME - Get Free Report) a

Athira Pharma (NASDAQ:LONA) & Prime Medicine (NASDAQ:PRME) Financial Review

Prime Medicine (NASDAQ: PRME - Get Free Report) and Athira Pharma (NASDAQ: LONA - Get Free Report) a

LeonaBio Appoints Industry Veteran Mark F. Kubik as Chief Business Officer

Brings more than 25 years of biopharma business development and corporate strategy expertise Brings